Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04318938
Title Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Indications
Therapies
Age Groups: senior | adult
Covered Countries DEU

Additional content available in CKB BOOST